Cerevel Therapeutics Holdings, Inc. (CERE)
After hours:
| Previous close | 24.44 |
| Open | 24.81 |
| Bid | 15.00 x 1000 |
| Ask | 36.67 x 1000 |
| Day's range | 22.95 - 25.25 |
| 52-week range | 12.01 - 46.16 |
| Volume | |
| Avg. volume | 430,667 |
| Market cap | 3.698B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.71 |
| Earnings date | 09 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.83 |
- Simply Wall St.
Here's Why We're Not Too Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- GlobeNewswire
Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial in focal epilepsy now expected mid-year 2023, revised from 2H 2022 $550.9M in cash, cash equivalents and marketable securities as of March 31, 2022; additional $37.5M from tavapadon risk-sharing arrangement received in April 2022 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Th
- GlobeNewswire
Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022
CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the U.S. financial markets open. Management will host a conference call to discuss first quarter 2022 financial results and recent business updates on Tuesday, May 10, 2022 at 8:00 a.m. ET. To access the call, please
